Identification of G-quadruplex DNA/RNA binders: Structure-based virtual screening and biophysical characterization by Rocca, Roberta et al.
Original Citation:
Identification of G-quadruplex DNA/RNA binders: Structure-based virtual screening and biophysical
characterization
Elsevier B.V.
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3223646 since: 2017-12-12T09:24:21Z
10.1016/j.bbagen.2016.12.023
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
  	

Identification of G-quadruplex DNA/RNA binders: Structure-based virtual
screening and biophysical characterization
Roberta Rocca, Federica Moraca, Giosue` Costa, Matteo Nadai, Matteo
Scalabrin, Carmine Talarico, Simona Distinto, Elias Maccioni, Francesco
Ortuso, Anna Artese, Stefano Alcaro, Sara N. Richter
PII: S0304-4165(16)30517-7
DOI: doi:10.1016/j.bbagen.2016.12.023
Reference: BBAGEN 28723
To appear in: BBA - General Subjects
Received date: 14 October 2016
Revised date: 20 December 2016
Accepted date: 21 December 2016
Please cite this article as: Roberta Rocca, Federica Moraca, Giosue` Costa, Matteo Nadai,
Matteo Scalabrin, Carmine Talarico, Simona Distinto, Elias Maccioni, Francesco Ortuso,
Anna Artese, Stefano Alcaro, Sara N. Richter, Identiﬁcation of G-quadruplex DNA/RNA
binders: Structure-based virtual screening and biophysical characterization, BBA - Gen-
eral Subjects (2016), doi:10.1016/j.bbagen.2016.12.023
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 1 
Identification of G-quadruplex DNA/RNA binders: Structure-based virtual 
screening and biophysical characterization 
Roberta Rocca
1§
,
 
Federica Moraca
1§
, Giosuè Costa
1*
, Matteo Nadai
2
, Matteo Scalabrin
2
, Carmine 
Talarico
1
, Simona Distinto
3
, Elias Maccioni
3
, Francesco Ortuso
1
, Anna Artese
1
, Stefano Alcaro
1*
, 
Sara N. Richter
2
 
 
 
1
Dipartimento di Scienze della Salute, Università degli Studi "Magna Graecia" di Catanzaro, Campus 
“Salvatore Venuta”, viale Europa, 88100, Catanzaro, Italy. 
2
Department of Molecular Medicine, University of Padua, via Gabelli 63, 35121, Padua, Italy. 
3Dipartimento di Scienze della Vita e dell’Ambiente, Università degli Studi di Cagliari, via Ospedale 72, 
Cagliari 09124, Italy. 
 
§ 
Equal Contributors 
 
*Corresponding Authors: Stefano Alcaro (alcaro@unicz.it) and Giosuè Costa (gcosta@unicz.it), Università 
degli Studi "Magna Graecia" di Catanzaro, Campus “Salvatore Venuta”, viale Europa, 88100, Catanzaro, 
Italy; Phone +39 0961 3694197; Fax +39 0961 391270. 
 
Running Title: Naphthyridin and chromen derivatives as DNA/TERRA-RNA binders.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 2 
ABSTRACT  
Background: Recent findings demonstrated that, in mammalian cells, telomere DNA (Tel) is 
transcribed into telomeric repeat-containing RNA (TERRA), which is involved in fundamental 
biological processes, thus representing a promising anticancer target. For this reason, the discovery 
of dual (as well as selective) Tel/TERRA G-quadruplex (G4) binders could represent an innovative 
strategy to enhance telomerase inhibition. 
Methods: Initially, docking simulations of known Tel and TERRA active ligands were performed 
on the 3D coordinates of bimolecular G4 Tel DNA (Tel2) and TERRA (TERRA2). Structure-based 
pharmacophore models were generated on the best complexes and employed for the Virtual 
Screening of  ̴ 257000 natural compounds. The 20 best candidates were submitted to biophysical 
assays, which included circular dichroism and mass spectrometry at different K
+
 concentrations.  
Results: Three hits were here identified and characterized by biophysical assays. Compound 7 acts 
as dual Tel2/TERRA2 G4-ligand at physiological KCl concentration, while hits 15 and 17 show 
preferential thermal stabilization for Tel2 DNA. The different molecular recognition against the two 
targets was also discussed. 
Conclusions: Our successful results pave the way to further lead optimization to achieve both 
increased selectivity and stabilizing effect against TERRA and Tel DNA G4s.  
General Significance: The current study combines for the first time molecular modelling and 
biophysical assays applied to bimolecular DNA and RNA G4s, leading to the identification of 
innovative ligand chemical scaffolds with a promising anticancer profile.  
 
 
Keywords: G-quadruplex DNA | TERRA | Virtual Screening | Circular Dichroism | Mass 
Spectrometry 
 
 
Abbreviations: G4s, G-quadruplex structures; Tel, telomeric DNA G-quadruplex; Tel2, bimolecular 
telomeric DNA G-quadruplex; TERRA2, bimolecular telomeric repeat-containing RNA G-
quadruplex; PDS, pyridostatin; cPDS, carboxypyridostatin; AR, aromatic ring feature; HY, 
hydrophobic feature; PI, positive ionisable feature; HBD, H-bond donor feature; HBA, H-bond 
acceptor feature; CD, circular dichroism; BA, binding affinity. 
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1. INTRODUCTION 
Beyond the canonical double helix [1], both DNA and RNA nucleic acids can also adopt non-
canonical higher-order structures called G-quadruplexes (G4s). G4s are formed in single-stranded 
guanine-rich (G-rich) sequences. In these G-rich sequences, four guanines can self-associate into a 
square-planar platform, called G-quartet, where each guanine is linked through Hoogsteen-type 
hydrogen bond network and the oxygen O6 atoms are arranged to coordinate metal cations. G-
quartets can π-stack upon each other forming four-stranded helical structure known as G4s [2]. In 
these last years, several studies reported that both DNA and RNA G4s are associated with many 
important biological processes [3, 4]. Specifically, DNA G4s have been shown to form into 
biologically significant regions of the genome, such as human telomeres (composed of TTAGGG 
repeats) [5], oncogene promoter regions [6], immunoglobulin switch regions [7] and ribosomal 
DNA [8]. By contrast, RNA sequences forming G4s motifs have been retrieved from the human 
transcriptome, particularly at the 5’ untranslated regions (UTRs) of mRNAs, which have been 
shown to be involved in the post-transcriptional regulation of gene expression [9]. In addition to the 
5’-UTRs regions, a recent study has shown that also mammalian telomeres can be transcribed into 
telomeric repeat-containing RNA (referred to as TERRA) containing UUAGGG repeats forming 
G4s conformations of heterogeneous length [10]. The direct evidence of the presence of the 
parallel-stranded TERRA RNA G4s in living cells has been also demonstrated by using a light-
switching pyrene probe by Xu and co-workers [11]. Such an evidence provided a useful information 
to deeper understand the structure and the biological function of TERRA RNA G4. In fact, it has 
been hypothesized that the presence of TERRA at the chromosome ends may represent a new level 
of regulation and protection of telomere, suggesting a possible association between TERRA RNA 
and telomere DNA (Tel), with a possible clinical relevance in the treatment of cancer. All such 
findings can trace the route for a new anticancer strategy based on ligands that selectively (or not) 
bind to the RNA G4s. The availability of telomeric RNA G4 experimental structures (NMR and X-
Ray) and a deep understanding of their topologies are crucial to design RNA G4s selective ligands. 
In fact, a little structural diversity has been found, in telomeric RNA G4 with respect to its DNA G4 
counterpart. CD, NMR, and X-ray crystallography have shown that G-rich telomeric RNA 
sequences form bimolecular parallel G4s (TERRA2) both under Na
+
 and K
+
 conditions [12-14]. 
Recently, Neidle et al. have solved the bimolecular crystal structure of a telomere RNA G4 (PDB 
code: 3MIJ) complexed with two molecules of a triazole-acridine derivative stacked side-by-side 
onto a single terminal 5’ G-quartet face [15]. In a recent work, Collie et al. have reported the higher 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 4 
selectivity of a naphthalene diimide ligand –bearing hydroxyl groups (compound c in Fig. 1) in 
binding bimolecular RNA G4s with respect to BRACO-19, which, in turn, has higher affinity for 
Tel DNA G4. Such an observation could be due to the presence of the 2’-OH groups in the ribose 
sugar at the apices of the RNA G4, which may constrict the space available to the ligand side-chains 
to interact with the loops by reducing the depth and the width of the UUA loops [16]. Therefore, the 
presence of multiple hydrogen bonds involving the O2′ hydroxyl groups of the ribonucleotide 
sugars in RNA G4s could be an important structural feature to be taken into account when 
designing selective RNA vs DNA G4-ligands [17]. The small molecule pyridostatin (PDS) 
(compound f in Fig. 1) was proved to be a generic dual bimolecular Tel DNA and TERRA G4 
binder, contrary to its derivative carboxypyridostatin (cPDS) that exhibited high molecular 
selectivity for unimolecular RNA over DNA G4s [18]. Overall, based on such data, telomere 
TERRA RNA G4s could represent a potential target for anticancer agents directed against 
telomeres. Therefore, finding novel dual (as well as selective) G4 Tel DNA and TERRA binding 
ligands could represent an innovative strategy to enhance telomerase inhibition [19]. 
Herein, to identify novel dual (or selective) Tel DNA and TERRA G4s binders we have employed a 
receptor-based virtual screening approach based on molecular docking and pharmacophore models 
targeting the bimolecular DNA G4 (Tel2) of the 12-nt telomeric sequence 5'-TAGGGTTAGGGT-3' 
(PDB code: 3CE5) [20] and its bimolecular RNA counterpart (TERRA2) telomeric sequence 12-nt 
5'-UAGGGUUAGGGU-3' (PDB code: 2KBP) [13]. The selected best candidates were submitted to 
biophysical evaluation. Among the 20 tested candidates, hit 7 (Supplementary Fig. 4), having a 2-
(6,7-dimethoxy-8-oxo-8H-benzo[c]indolo[3,2,1-ij][1,5]naphthyridin-12-yl)oxy scaffold, came out 
as the most interesting Tel2/TERRA2 dual binder, not only from the theoretical approach but also 
from biophysical data which confirmed its “dual” activity since it showed good stabilization against 
both Tel2 and TERRA2. In addition, hits 15 and 17 (Supplementary Fig. 5) have been retrieved as 
interesting selective Tel2 binders and further lead optimization studies could be undertaken in order 
to improve their affinity against Tel2 or to achieve a certain activity over TERRA2. This work paves 
the way to understand at atomistic level the molecular features needed to obtain Tel/TERRA G4 
binders through a Virtual Screening approach.  
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2. MATERIAL AND METHODS 
2.1 Receptors preparation. The bimolecular human telomeric Tel2 and TERRA2 G4s, having PDB 
codes 3CE5 [20] and 2KBP [13] respectively, were selected to perform the structure-based virtual 
screening procedure since their sequence and topology were fully comparable. In particular, the 
PDB model 3CE5 represents the bimolecular X-ray structure (resolution of 2.5 Å) of the telomeric 
sequence 5'-TAGGGTTAGGGT-3', complexed with the known active ligand BRACO-19 in the 
presence of physiological concentrations of K
+
. The binding site of the ligand, BRACO-19, derived 
from the 3,6,9-trisubstituted acridine, is located at the interface of two G4 monomers both with 
parallel topology, included between a G-tetrad surface and a tetrad TATA. Indeed, the NMR PDB 
model 2KBP represents the ribonucleic sequence 5'-UAGGGUUAGGGU-3 ' in the presence of K
+ 
ion, equivalent to that of the 3CE5 model. In this study, both the X-Ray and NMR models were 
prepared and refined using the Protein Preparation Wizard implemented in Maestro ver. 9.7 [21] 
and, in addition, also the corresponding minimized structures were considered. With this aim, 5000 
steps of the Polak Ribiere conjugate gradient algorithm [22]
 
and the OPLS 2005 force field with the 
united atoms notation [23] as implemented in MacroModel version 10.3 [24] were used. A 
convergence criterion equal to 0.05 kJ·mol
−1
·Å was adopted and solvent effects were taken into 
account by means of the GB/SA implicit water solvation model [25]. 
2.2 Actives and Decoys set preparation. A test set of 9 known active G4 ligands a-i (Fig. 1) 
characterized by different chemical scaffolds, were collected from literature data [26, 27]. They 
were selected based on their experimental affinity and activity toward bimolecular TERRA2 and 
Tel2 G4s and their selectivity with respect to duplex DNA.  
Please put Figure 1 here 
The decoy set was taken from the Directory of Universal Decoys (DUD) [28], which provided a 
library of 419 compounds, based on the structural similarity with respect to the active set. Both 
actives and decoys set were prepared considering the ionization state at physiological pH of 7.4 
using the OPLS 2005 force field as implemented in the LigPrep platform ver. 2.9 of Maestro [29].   
2.3 Molecular Docking protocol. In order to evaluate the accuracy and reliability of our docking 
protocol, we firstly used the SP (Standard Precision) scoring function of Glide ver. 6.2 software 
from Schrodinger suite [30] to perform redocking calculations of BRACO-19 against 3CE5 PDB 
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model, in order to geometrically reproduce the bioactive conformation. The obtained poses with the 
related RMSD (Root Mean Square Deviation) values are shown in Figure S1 of the Supplementary 
Materials (Supplementary Fig. 1). BRACO-19 was treated as flexible, while the receptor was kept 
rigid. The energy grid was built centering the docking box on guanine core and setting its outer box 
size to 45×45×45 Å. The scaling factor for the receptor Van der Waals radii was set to 1.0 and the 
number of generated poses was equal to 10. Following this protocol, docking simulations of the 9 
actives and 419 decoys were carried out using the same redocking conditions for both Tel2 and 
TERRA2 G4s receptors.  
2.4 Enrichment factor studies. In order to take into account the effects of receptors flexibility, an 
ensemble of receptor conformations has been created (Supplementary Table 1). In particular, in the 
case of the X-Ray model of Tel2 (PDB ID: 3CE5), both the crystallographic and the minimized 
structures were considered for each of these different conditions: i) in presence of the complexed 
ligand BRACO-19; ii) in absence of the complexed ligand BRACO-19; iii) with waters; iv) without 
waters. Indeed, for TERRA2, since its NMR model (PDB ID: 2KBP) contains 10 conformers, we 
decided to consider both experimental and minimized structures. Globally, 26 ensemble structures 
have been used for enrichment calculations (Supplementary Table 1), in order to select the 
ensembles of up to 2 receptors, which lead to improved enrichment results of the actives set [31]. 
The following descriptors have been taken into account: area under the curve (AUC), receiver 
operating characteristic (ROC), enrichment factor (EF), robust initial enhancement (RIE) and 
Boltzmann-enhanced discrimination of ROC (BEDROC). Docking calculations were performed 
using the Glide SP software. Among all the ensemble receptors, only the up to 2 receptors with the 
best AUC and RIE data were chosen (Figs. 2A and 2B), as able to discriminate the largest number 
of active compounds and to rank them within the top-score hits. Their AUC and RIE values are 
highlighted in bold in the supplementary Table 1, whereas their % Active compound screen plots 
are shown in the supplementary Fig. 2. 
Please put Figure 2 here 
2.5 Structure-based pharmacophore generation. The 3D Structure-based pharmacophores were 
developed by means of the software LigandScout ver. 3.1 [32] on the best ranked docked pose of 
the 9 actives obtained against the previously validated ensemble receptor (Figs. 2A and 2B). From 
the best docking complexes, the 3D pharmacophore models were automatically generated by 
LigandScout using predefined features, such as hydrogen bond acceptor (HBA), hydrogen bond 
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donor (HBD), hydrophobic (HY), negative ionizable (NI), positive ionizable (PI), aromatic ring 
(AR). Thus, the obtained pharmacophores were further modified increasing or decreasing the radius 
of tolerance of the previous features, inserting the excluded volumes in order to better describe the 
shape of the binding cavity and boost the complexity of the pharmacophore [33]. In particular, we 
manually modified the starting automatic pharmacophores on the basis of the information regarding 
DNA or RNA G4/ligand interactions reported in literature data and they are described in Results 
paragraph.  
2.6 Structure-based pharmacophore validation. This procedure was performed using the same 
active/decoys set already used in the enrichment study. The hypotheses were evaluated on their EF 
and ROC curve. We used the Enrichment Factor (EF) as validation descriptor [34-35], that was 
calculated, for all the generated hypotheses, using the following eq. A.1: 
𝐸𝐹 =
𝑇𝑃 𝑛⁄
𝐴 𝑁⁄
            (Eq. A.1) 
where TP is the number of True Positive, n is the number of active and inactive compounds found 
from the pharmacophore hypothesis, A is the number of active compounds in the database and N is 
the database size (total of actives and inactives).  
After evaluating the hypotheses based on the EF, the best ones were selected taking into account 
also the Receiver operating characteristic (ROC) curve and the percentage of the actives found for 
each hypothesis (Tables 2-3 of the Results section). In particular, an ideal ROC curve, where no 
overlap between the scores of active molecules and decoys exists, proceeds from the origin to the 
upper-left corner until all the actives are retrieved and the sensitivity (Se) reaches the value of 1. 
Further details are reported in the Results paragraph. The validated pharmacophore models are 
reported in Figs. 3-4. 
2.7 Database preparation and Virtual Screening (VS). Each of the ten selected and validated 
pharmacophore models (Figs. 3-4) was used to perform VS separately using a multi-conformational 
database of natural compounds imported from the ZINC website. It included also the NPD 08 
database developed by the University of Innsbruck, for a global number of  ̴ 257000 natural 
compounds. A physically relevant ionization state (pH=7.4) was assigned to all compounds and the 
stereochemistry of chiral centres was determined. Afterwards, the so prepared database was 
subjected to an energy minimization step using the same protocol adopted for actives and decoys set 
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[13]. Hence, two databases were created: one including the merged hits identified for each 
pharmacophore model of Tel2, the second formed by the merged hits found for TERRA2 RNA G4. 
The resulting two databases for TERRA2 and Tel2 were de-duplicated and further reduced in size by 
applying the popular empirical Lipinski’s rule of five. Molecules that successfully passed this filter 
were further submitted to docking studies.  
2.8 Similarity clusterization. To reduce the number of compounds to be tested on Tel2, we 
clustered the obtained hits on the basis of their volume overlap, using the average Linkage method. 
Finally, for each cluster we selected the compound with the best Glide Score (GScore).  
2.9 Selection for biological testing. After the careful visual inspection analysis of the best docking 
poses and the evaluation of their commercial availability, the best 20 final hits were purchased and 
submitted to biological tests. 
2.10 Oligonucleotides used in the biophysical analysis. All desalted oligonucleotides were 
purchased from Sigma-Aldrich, Milan, Italy (Table 1). 
Please put Table 1 here 
 
2.11 Circular dichroism analysis. CD spectra were recorded on a Chirascan-Plus (Applied 
Photophysics, Leatherhead, UK) equipped with a Peltier temperature controller using a quartz cell 
of 5-mm optical path length and scanning a speed of 50 nm/min with a response time of 4 sec over a 
wavelength range of 230-320 nm. The reported spectrum of each sample represents the average of 2 
scans. Observed ellipticities were converted to mean residue ellipticity (θ) = deg x cm2 x dmol-1 
(Molar Ellipticity). Oligonucleotides were diluted from stock to the final concentration (4-8 μM 
single strand concentration) in Li cacodylate buffer (10 mM, pH 7.4) with 100 mM (or 5 mM or 2 
mM) KCl and then annealed by heating at 95 °C for 5 min, gradually cooled to room temperature. 
Compounds were added at 2x G4 final concentration (8-16 μM). CD spectra were recorded after 24 
h from 20°C to 95°C, with temperature increase of 5°C. Tm values were calculated according to the 
van’t Hoff equation, applied for a two state transition from a folded to unfolded state, assuming that 
the heat capacity of the folded and unfolded states are equal [36]. 
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2.12 Mass spectrometry analysis. Oligonucleotides (20 μM) in 1 mM KCl, 150 mM 
trimethylammonium acetate pH 7.0 (TMAA) where annealed by heating at 95 °C for 5 min and 
gradually cooling to room temperature. Afterward isopropanol (IPA) was added to the 
oligonucleotides (20% of the total volume) before incubating overnight at 4 °C (final buffer 
composition: 0.8 mM KCl, 120 mM TMAA pH 7.0, 20 % IPA). The folded oligonucleotides where 
mixed together (Tel2/TERRA2, Tel2/dsDNA, TERRA2/dsDNA, each oligo final concentration 2 
µM) and incubated with the tested compound at ratio oligo: compound 1:2 for 1h at 4 °C. Samples 
were analyzed by direct infusion electrospray ionization (ESI) on a Xevo G2-XS QTof mass 
spectrometer (Waters, Manchester, UK). The injection was automatically performed by an Agilent 
1290 Infinity HPLC (Agilent Technologies, Santa Clara, CA, US) equipped with an auto sampler; 
the carrying buffer was TMAA 80 mM pH 7.0, 20% IPA. 5 μL of each sample were typically 
injected for each analysis. The ESI source settings were the following: electrospray capillary 
voltage set at 1.8 kV, the source and the desolvation temperatures were 45 °C and 65 °C 
respectively, the sampling cone was set at 75 V. All these parameters ensured minimal 
fragmentation of the DNAs complexes. The instrument was calibrated using a 2 mg/mL solution of 
sodium iodide in 50% of IPA. Additionally, the use of the LockSpray during the analysis provided a 
typical <5 ppm mass accuracy. The internal standard LockSpray consisted in a solution of leu-
enkephalin 1 μg/mL in acetonitrile/water (50:50, v/v) containing 0.1% of formic acid. Binding 
affinities were calculated for each experiment using the intensity of each species calculated by 
MassLynx V4.1. The binding affinity was calculated with the following formula: [BA = 
(ΣNAb/(ΣNAf + ΣNAb)) × 100], where BA is the binding affinity, NAb is the intensity of the 
bound nucleic acid peaks, NAf is the intensity of the free nucleic acid peaks. NAb comprises 
DNA/RNA with one or more bound ligands, where present. Signals with charge states, 5−, and 4− 
were used. Only dimeric DNA/RNA coordinating two potassium ions or duplex DNA where 
included in the calculation. 
 
3. RESULTS 
3.1 Generation of Tel2 Structure-based pharmacophore models. In this study, five different 
docking complexes for bimolecular DNA G4 (Tel2) were selected as input for structure-based 
pharmacophore generation. Similarly, to the crystallographic pose of BRACO-19, we observed a 
preference for the bottom position in the recognition of Tel2 in the complexes of four hypothesis (D-
Hypo1, D-Hypo2, D-Hypo3, D-Hypo4), in which the planar portion of ligands was sandwiched 
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between residues DG11 and DT12. In contrast, in the D-Hypo5 the binding site was identified in the 
loop of Chain A. Specifically, D-Hypo1 was generated starting from the docking complex of 
Naphtalene diimide with a bis-dimethylaminopropyl-hydroxypropylamino side chain (compound c 
in Fig. 1), involved in several hydrogen bonds interactions established with the phosphodiesterasic 
portion of residues DG11 and DG16 and the carboxyl groups of DT24. The carboxyl group of the 
aromatic core was found to interact by means of a hydrogen bond with DT24, too. In D-Hypo2, Tel2 
was recognized by BRACO-19 (e) and it was stabilized by two hydrogen bonds formed between the 
phosphors of residues DT12 and DG17 with the two pyrrolidine rings of the ligand. In D-Hypo3, 
the 9-Fluoro-2-methyl-5H-thiocromeno[4,3-d] pyrimidine (compound g in Fig. 1) interacted with 
Tel2 only by means of stacking interactions. D-Hypo4 described the way in which 2-chloro-6-
fluoro-N-(4-fluoro-1-methyl-1H-indazol-3-yl)benzamide (compound h in Fig. 1) interacted with 
Tel2, with the establishment of two hydrogen bonds between the ligand amide group and residues 
DG11 and DT12. In the last D-Hypo5, 2-(2-Fluorophenyl)-N-[(5-methyl-2-
thienyl)methyl]ethanamine (compound i in Fig. 1) was stabilized in the complex through one 
hydrogen bond between the ligand amine group and the oxygen of the DG5 furanose.  
We decided to select all the generated five pharmacophore hypothesis, that are represented in Fig. 3, 
due to the good EF values for D-Hypo2, D-Hypo3, D-Hypo4, D-Hypo5 and the high percentage of 
active compounds and the ROC curve (Supplementary Fig. 3A) for D-Hypo1. Details about the 
features are reported in Table 2 and discussed in the Discussion section.   
Please put Figure 3 here 
Please put Table 2 here 
 
 
3.2 Generation of TERRA2 Structure-based pharmacophore models. As concerns the 
bimolecular telomeric RNA G4 (TERRA2), eight pharmacophore hypotheses were generated; their 
feature details are reported in Table 3 and more thoroughly discussed in Discussion section. Also in 
the TERRA2, the bottom position was the preferred binding site, probably because at the top 
position residues RU1 and RU13 interact with each other, thus limiting the exposure of the planar 
G-tetrad formed by RG3:RG9:RG15:RG21 residues. Consequently, more favourable interactions 
between the planar moieties of the ligands are established with RG5, RG11 and RG23 residues. 
Specifically, the T-Hypo1 was generated from the docking complex of the Naphtalene diimide with 
a dimethylamino-propyl side chain (compound a in Fig. 1) whose positively charged side chains 
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engage electrostatic interactions with the phosphodiesterasic portion of TERRA2. Similar binding 
modes were observed in the docking complexes of the Naphtalene diimide having the propylamino-
pyrrolidin side chains (compound b in Fig. 1) and the Naphtalene diimide with the bis-
dimethylamino-propyl-hydroxypropyl side chains (compound c in Fig. 3), represented, respectively, 
in T-Hypo2 and T-Hypo3. The only difference of compound b was related to the establishment of 
one hydrogen bond between a pyrrolidine nitrogen with a carboxyl group of residue RU24. In 
contrast, for compound c, the two hydroxyl groups interact by means of two hydrogen bonds with 
residues RU6 and RU12. T-Hypo4 describes the complex of Acridine (compound d in Fig. 1) with 
TERRA2, in which two electrostatic interactions, between the positively charged nitrogen atom of 
the ligand side chain and the phosphodiesterasic portion of RA8 and RU24 residues, further 
stabilized the binding mode. In T-Hypo5 (Supplementary Fig. 4), TERRA2 was recognized by PDS 
(Pyridostatin) (compound f in Fig. 1), and it was stabilized by three electrostatic interactions among 
the positively charged nitrogen atom of the moieties and the phosphodiesterasic groups and by one 
hydrogen bond established between a ligand carboxyl group and RU24. The 9-Fluoro-2-methyl-5H-
thiocromeno[4,3-d] pyrimidine (compound g in Fig. 1), whose binding mode was described in T-
Hypo6, established two hydrogen bonds with residues RU12 and RG17, contrary to its binding 
mode on the Tel2 where it interacted only through stacking interactions. The complex of 2-chloro-6-
fluoro-N-(4-fluoro-1-methyl-1H-indazol-3-yl)benzamide (compound h in Fig. 1) with TERRA2 was 
represented by T-Hypo7 (Supplementary Fig. 4) and was characterized only by stacking 
interactions. Finally, T-Hypo8 (Supplementary Fig. 4) described the binding mode of 2-(2-
Fluorophenyl)-N-[(5-methyl-2-thienyl)methyl]ethanamine (compound i in Fig. 1) on TERRA2, 
characterized by several stacking interactions and one hydrogen bond with residue RU24. 
We decided to select only five pharmacophore hypotheses (Fig. 4). In particular, T-Hypo1, T-
Hypo2, T-Hypo3 and T-Hypo4 were selected due to the good EF values, while T-Hypo6 was 
chosen taking into account its ROC curve (Supplementary Fig. 3B) and the high percentage of 
active compounds found.  
Please put Figure 4 here 
Please put Table 3 here 
 
 
3.3 Database screening. From the above validation methods, it turned out that five pharmacophore 
hypotheses for Tel2 and five for TERRA2 had a good ability to distinguish the active from decoy 
sets and to retrieve the greatest number of active compounds. These best pharmacophores were used 
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separately to screen a database of around ~260000 compounds. The ranked molecules identified for 
each Tel2 pharmacophore model were merged, thus obtaining 18725 hits for the deoxyribonucleic 
G4 and the same procedure was performed for hits resulting from virtual screening of TERRA2, 
collecting 16578 molecules. Then, Lipinski’s rule of five was used to eliminate the non-drug like 
compounds from the hit molecules thus obtaining 12212 and 12387 molecules respectively for Tel2 
and TERRA2 that were further subjected to ensemble docking simulations on their theoretical 
target. 
3.4 Molecular docking studies. Molecular docking was performed on Tel2 and TERRA2 to allow 
the investigation of the potential binding orientations of the databases hit compounds and select 
them by their binding affinity score. With this aim, in order to have a reasonable cut-off, we used 
the average GScore obtained from the active compounds against Tel2 and TERRA2, respectively of 
-9.64 and -8.98 kcal/mol. Thus, the top-ranked 91 hits for Tel2 and 14 hits for TERRA2 were 
obtained. Afterwards, given the high number of top-ranked hits, they were clustered considering 
their molecular diversity (see the “Similarity clusterization” paragraph) and finally 32 hits were 
selected for their scaffold diversity. Unfortunately, after investigating their commercial availability, 
only 20 hits were purchased from several chemical suppliers (seven hits from TERRA2 and thirteen 
from Tel2) and submitted for biophysical assays. The 2D structures of the 20 hits are shown in 
supplementary Figs. 5 and 6, while their Glide SP Score (GScore) values are reported in the 
supplementary Table 2.   
3.5 Circular dichroism screening. The available hits were screened for their ability to stabilize the 
bimolecular G4 targets by melting circular dichroism spectroscopy (CD). This technique allowed us 
to discriminate quadruplex topologies and to calculate melting temperatures (Tm) both in the 
absence and presence of the compounds.  
Hits 1-7 and 8-20, selected by the computational screening as putative binders of TERRA2 and Tel2, 
respectively, were initially tested against their computationally defined targets (Tables 4-5). Hit 7 
was the only candidate able to stabilize TERRA2, with a ΔTm of 6.8 °C (Table 4), while hits 15 and 
17 were the best stabilizers of Tel2. 
Please put Table 4 here 
 
The three best active hits did not modify the dimeric propeller-like parallel G4 conformation of 
TERRA2 [13-14], the CD spectrum of which was characterized by a negative peak at 240 nm and a 
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positive peak at 265 nm also in the presence of the compounds (Figs. 5 A-B and supplementary Fig. 
7). In contrast, they modified the mixed-type conformation of Tel2. In particular, the CD spectrum 
of the oligonucleotide itself showed a negative peak at 240 nm, a positive peak at 265 nm and a 
shoulder at 295 nm (Fig. 5 C), as the result of two interconverting conformations [37-38]. In the 
presence of the compounds the equilibrium was shifted towards the parallel-like topology, resulting 
in the decrease of the shoulder at 295 nm and increase of the dichroic signal at 265 nm, especially 
for hits 15 and 17 (Figs. 5 D-F).  
 
Please put Figure 5 here 
 
Because TERRA2 was much more stable that Tel2 at 100 mM (Tm 71.0°C and 52.6, respectively) 
(Table 5), we reasoned that the stabilization imparted by the compounds would have been naturally 
more pronounced in the intrinsically less stable oligonucleotide, i.e. Tel2. To test this hypothesis, we 
decreased K
+
 concentration to 5 and 2 mM to obtain Tm values for TERRA2 similar to those of Tel2. 
TERRA2 Tm at 2 mM K
+
 (54.3°C) became comparable to Tel2 Tm at 100 mM K
+
 (52.6°C). Indeed, 
at lower K
+
 concentration, all hits were able to stabilize TERRA2 to a greater extent (Table 5) and at 
2 mM K
+
 hits 15 and 17 stabilized Tel2 and TERRA2 by the same ΔTm. The one exception was hit 7 
on TERRA2 at 2 mM K
+
, conditions at which destabilization rather than stabilization of the G4 
structure was obtained. This last data may be an indication that TERRA2 G4 folding in such low K
+
 
concentration is so poor that stabilization is detected only by compounds able to induce the G4 
conformation. These data indicate that a meaningful direct comparison of the binding efficiency 
towards oligonucleotides with different Tm is hardly achievable by CD. 
 
Please put Table 5 here 
 
3.6 Mass Spectrometry (MS) Competition Assay. To detect which of the two G4 oligonucleotides 
(TERRA2 or Tel2) was preferentially bound by the selected hits, an electrospray mass spectrometry 
method was set up. The gentle ionization conditions of electrospray allow to transfer intact 
biomolecules and non-covalent complexes in the gas phase to obtain a snap-shot of the species 
present in solution and their relative concentration [39-40]. By the relative intensity of the 
bound/unbound species, it is possible to gather information on the relative binding affinities and the 
specificity toward the different investigated oligonucleotides [41-42]. In our experimental 
procedure, TERRA2 and Tel2 were separately folded and mixed just before the addition of the tested 
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compounds to minimize formation of hybrid DNA/RNA G4s. Surprisingly, the formation of the 
hybrid species was not observed, even after extended incubation times (i.e. up to 16 h) 
(Supplementary Fig. 8). Both TERRA2 and Tel2 were detected mostly as dimers, as evinced by the 
coordination of two K
+
 ions, which is consistent with the formation of dimeric G4s with three 
guanine quartets. The monomeric peak was almost absent in TERRA2 solution, while was 
detectable, even though at low level, in the Tel2 sample, confirming the lower stability of the Tel2 
G4. Double-stranded DNA (dsDNA) was also used alongside the G4 folded oligonucleotide to test 
the hits’ selectivity towards G4s. DsDNA did not modify G4 formation (Supplementary Fig. 9). 
Each compound was competed for the binding to TERRA2/Tel2, TERRA2/dsDNA, Tel2/dsDNA 
(Table 6) (Fig. 6 and supplementary Figs. 10-12). The relative binding affinities (BA) calculated by 
the intensity of the peaks are reported in Table 6. Interestingly, no adducts to monomeric RNA or 
DNA were obtained (Fig. 6 and supplementary Figs. 10-12).   
Hit 7 showed a much higher affinity for TERRA2 compared to Tel2 and dsDNA (Table 6, Fig. 6 and 
supplementary Fig. 10); hit 15 displayed a slightly higher affinity for Tel2 vs TERRA2 and low 
affinity for dsDNA (Supplementary Fig. 11); hit 17 showed similar BA towards TERRA2 and Tel2 
and low binding affinity towards dsDNA (Supplementary Fig. 12). The affinity towards dsDNA 
was similarly low for all compounds (Table 6). 
 
Please put Table 6 here 
Please put Figure 6 here 
 
3.7 Pharmacophore analysis between Tel2 vs TERRA2. The interesting results obtained from 
experimental data against Tel2 and TERRA2 for hits 7, 15 and 17 led us to analyze in detail the 
differences between the pharmacophore models of TERRA2 (T-Hypo) and Tel2 (D-Hypo). The D-
Hypo2 and the T-Hypo4, respectively for Tel2 and TERRA2, were equally able to discover the hit 7 
(Fig. 7 A-B). The two pharmacophore models consist in the same type of features (2 HBD, 1 AR) 
with very similar interatomic distances (Fig. 7 C-D), thus justifying the dual activity of 7. Only the 
greater distance between the two HBD groups is mainly due to the flexibility of the side chain. The 
positive ionisable feature (PI) does not seem to be discriminant between the two targets. 
 
Please put Figure 7 here 
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Hit 15 was found only by the D-Hypo1 consisting of one AR, one HBD and one HBA 
(Supplementary Fig. 13 A-B). Also in this case the selectivity of this compound towards Tel2 can be 
explained by looking at the interatomic distance of the pharmacophore features that are much less 
spaced compared to those of T-Hypo4 and D-Hypo2 (Fig. 7 A-B) and the presence of one HBA.  
Hit 17 was retrieved only by D-Hypo3 (whose superimposition is shown in supplementary Fig. 14 
A-B). The lack of selectivity toward TERRA2 can be attributed to the absence of any HBD 
interactions as well as to the different spatial arrangement of the features that are very close to each 
other. 
 
3. 8 Docking pose analysis of best hits 7, 15 and 17. The Glide SP Score (GScore) of hits 15 and 
17 obtained against TERRA2 fall outside the threshold used to filter docking results (equal to -7.39 
and -7.22 kcal/mol, respectively), thus confirming their lower affinity for this target demonstrated 
also by ΔTm data at 100 mM K
+
. With the aim of clarifying the different affinity of 15 and 17 
between TERRA2 and Tel2, we analyzed the relative docking poses and the contacts (Table 7) by 
means of the Maestro graphical interface (Maestro Graphics User Interface, Schrödinger LLC, New 
York, NY, USA, 2016) [38, 39]. 
 
Please put Table 7 here 
 
As previously stated, all the three hits 7, 15 and 17 favourably interact in the same binding site for 
both Tel2 and TERRA2 located close to the guanine residues G5:G11:G17:G23 which, for Tel2, 
corresponds to the same binding site of BRACO-19 reported in the crystal structure (PDB ID: 
3CE5). In addition, hits 7, 15 and 17 are characterized by the presence of side chains with positively 
charged nitrogen atoms, able to engage in favorable salt-bridge and Hbond interactions with the 
phosphate backbone. However, the higher affinity to Tel2 G4 of 15 and 7 probably results from a 
sandwiched binding mode between their aromatic core and the thymine nucleobase at positions 12, 
thus justifying the increasing number of their good and stacking interactions against Tel2 (Table 7). 
The only exception is 17, which does not form any stacking interaction against Tel2, but is able to 
establish the highest number of good contacts with respect to its binding mode against TERRA2. In 
particular, residues RU12 and RU24 in TERRA2 G4 assume a conformation that does not allow the 
good accommodation of the ligand aromatic planar portion on the tetrad, since the lack of the 
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methyl group in the uracil and the resulting reduced steric hindrance of the hydrogen atom make 
these residues more flexible (Fig. 8 A-F). 
Please put Figure 8 here 
 
4. DISCUSSION 
As widely reported in literature, telomerase activity requires an unfolded single-stranded substrate. 
Hence, G4 formation directly inhibits telomerase elongation in vitro [43] and therefore ligands that 
selectively bind to and stabilize G4 structures may interfere with telomere conformation and 
telomere elongation. Since telomerase levels are high in the majority of malignant cells and largely 
absent in normal cells, these G4 ligands have been proposed as selective anti-cancer agents.  
Given the few number of available telomeric G4 RNA selective binders to date [26], our Virtual 
Screening approach can be considered the first step towards the discovery of novel promising 
ligands able to stabilize TERRA2 structures. In particular, our protocol allowed us to identify hit 7, 
characterized by a naphthyridin scaffold with a ((dimethylamino)propyl)acetamide side chain, as a 
dual Tel2/TERRA2 binder: hit 7 matches Tel2 and TERRA2 pharmacophore features that display 
very similar interatomic distances and angles, and it exerts good theoretical affinity for both 
structures, as gathered from docking calculations. In vitro, hit 7 displays thermal stabilization 
effects on both target nucleic acids even though with a visible preferential stabilization on TERRA2 
as gathered by both CD ad MS competition analysis. On the contrary, Hits 15 and 17, having 
respectively a furo-chromen and benzofuran scaffolds, show preferential tendency to stabilize Tel2 
G4 rather than its RNA counterpart. Such a finding probably relates to a reduced π-π interactions 
network of both hits due to lower accessibility of the G-tetrad surface linked to the steric hindrance 
of the terminal uracils RU12 and RU24. Moreover, a poor geometric overlapping between the 
pharmacophore features of TERRA2 with both hits 15 and 17 was observed, thus rationalizing their 
preferential recognition of Tel2. Compound 17 behaviour confirmed also our previous findings on 
the potential of the furo-chromen scaffold [44]. Optimization on this scaffold is already in progress. 
 
5. CONCLUSIONS 
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The molecular modelling and biophysical studies reported here allowed us to retrieve three novel 
promising stabilizers against Tel2/TERRA2 G4s. Specifically, the naphthyridin scaffold is here 
proposed as the most interesting one against TERRA2 and could be the starting point for a further 
lead optimization to enhance its telomeric RNA selectivity. On the other hand, the two derivatives 
with a furo-chromen and benzofuran scaffolds preferentially recognized Tel2: their affinity profile 
could thus be investigated also against other G4s topologies. Hit optimization could lead, in the 
future, to novel G4-ligand cores with potentially innovative conformational/sequence specificity. 
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C. González, Discovery of Selective Ligands for Telomeric RNA G-quadruplexes (TERRA) through 19F-
NMR Based Fragment Screening. ACS Chem. Biol. 9 (2014) 1559-1566. 
[27] G.W. Collie, G.N. Parkinson, The application of DNA and RNA G-quadruplexes to therapeutic 
medicines. Chem. Soc. Rev. 40 (2011) 5867-5892. 
[28] M.M. Mysinger, M. Carchia, J.J. Irwin, B.K. Shoichet, Directory of useful decoys, enhanced (DUD-E): 
better ligands and decoys for better benchmarking. J. Med. Chem. 55 (2012) 6582-6594. 
[29] LigPrep, version 2.5, Schrödinger, LLC, New York, NY, 2012. 
[30] Glide, version 6.2, Schrödinger, LLC, New York, NY, 2014. 
[31] S. Rao, P.C. Sanschagrin, J.R. Greenwood, M.P. Repasky, W. Sherman, R. Farid, Improving database 
enrichment through ensemble docking. J. Comput. Aided Mol. Des. 22 (2008) 621-7. 
[32] G. Wolber, T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound ligands and their 
use as virtual screening filters. J. Chem. Inf. Model. 45 (2005) 160–169. 
[33] R. Rocca, G. Costa, A. Artese, L. Parrotta, F.  Ortuso, E. Maccioni, O. Pinato, M.L. Greco, C. Sissi, S. 
Alcaro, S. Distinto, F. Moraca, Hit Identification of a Novel Dual Binder for h-telo/c-myc G-Quadruplex by 
a Combination of Pharmacophore Structure-Based Virtual Screening and Docking Refinement. 
ChemMedChem (2016) doi: 10.1002/cmdc.201600053. 
[34] D. Schuster, P. Markt, U. Grienke, J. Mihaly-Bison, M. Binder, S.M. Noha, J.M. Rollinger, H. 
Stuppner, V.N. Bochkov, G. Wolber, Bioorg Med Chem. 19 (2011) 7168–7180. 
[35] J. Kirchmair, P. Markt, S. Distinto, G. Wolber, T. Langer, Evaluation of the performance of 3D virtual 
screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn 
from earlier mistakes? J. Comput. Aided Mol. Des. 22 (2008) 213-228. 
[36] N.J. Greenfield, Using circular dichroism collected as a function of temperature to determine the 
thermodynamics of protein unfolding and binding interactions. Nat. Protoc. 1 (2006), 2527-2535. 
[37] A.T. Phan, D.J. Patel, Two-repeat human telomeric d(TAGGGTTAGGGT) sequence forms 
interconverting parallel and antiparallel G-quadruplexes in solution: distinct topologies, thermodynamic 
properties, and folding/unfolding kinetics. J. Am. Chem. Soc. 125 (2003), 15021-15027. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 20 
[38] G.N. Parkinson, M.P. Lee, S. Neidle. Crystal structure of parallel quadruplexes from human telomeric 
DNA. Nature, 417 (2002), 876-880. 
[39] F. Rosu, V. Gabelica, C. Houssier, E. De Pauw, Determination of affinity, stoichiometry and sequence 
selectivity of minor groove binder complexes with double-stranded oligodeoxynucleotides by electrospray 
ionization mass spectrometry, Nucleic Acids Res. 30 (2002) e82. 
[40] E.B. Erba, R. Zenobi, Mass spectrometric studies of dissociation constantsof noncovalent complexes, 
Annual Reports Section “C” (Physical Chemistry). 107 (2011) 199. doi:10.1039/c1pc90006d. 
[41] K.B Turner, Inhibitory effects of archetypical nucleic acid ligands on the interactions of HIV-1 
nucleocapsid protein with elements of –RNA, Nucleic Acids Research. 34 (2006) 1305-1316. 
doi:10.1093/nar/gk1004. 
[42] G. Yuan, Q. Zhang, J. Zhou, H. Li, Mass spectrometry of G-quadruplex DNA: Formation, recognition, 
property, conversion and condormation, Mass Spectrometry Reviews. 30 (2011) 1121-1142. 
doi:10.1002/mas.20315. 
[43] A. M. Zahler, J. R. Williamson, T. R. Cech, D. M. Prescott, Inhibition of telomerase by G-quartet DMA 
structures. Nature 350 (1991) 718-720. 
[44] S. Alcaro, C. Musetti, S. Distinto, M. Casatti, G. Zagotto, A. Artese, L. Parrotta, F. Moraca, G. Costa, F. 
Ortuso, E. Maccioni, C. Sissi, Identification and characterization of new DNA G-quadruplex binders selected 
by a combination of ligand and structure-based virtual screening approaches, J. of Med. Chem., 56 (2013) 
843-855. 
 
 
 
 
 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 21 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 22 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 23 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 24 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 25 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 26 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 27 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 28 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 29 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 30 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 31 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 32 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 33 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 34 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 35 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 36 
Highlights 
 TERRA G4, involved in crucial biological processes, could be an anticancer target. 
 First virtual screening performed on TERRA G4 structures.  
 We identified three novel promising stabilizers against Tel2/TERRA2 G4s.  
 The naphthyridin scaffold is proposed as the most interesting one against TERRA2. 
 A furo-chromen and a benzofuran derivatives preferentially recognized Tel2. 
